Senesco Technologies (OTCMKTS: SVON) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.
Earnings & Valuation
This table compares Senesco Technologies and Mateon Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Senesco Technologies||$80,000.00||167.18||-$5.79 million||($0.24)||-1.08|
|Mateon Therapeutics||N/A||N/A||-$13.65 million||($0.56)||-0.45|
This table compares Senesco Technologies and Mateon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Senesco Technologies has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Senesco Technologies and Mateon Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mateon Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 700.96%. Given Mateon Therapeutics’ higher probable upside, analysts clearly believe Mateon Therapeutics is more favorable than Senesco Technologies.
About Senesco Technologies
Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.
About Mateon Therapeutics
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
What are top analysts saying about Senesco Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Senesco Technologies Inc. and related companies.